Management of patients with two consecutive ASC-US smears

Introduction: To determine whether aggressive or expectative management of patients after two consecutive smears with atypical squamous cells of undetermined significance is preferable. To determine whether triage with high-risk human papillomavirus will identify all patients with cervical intraepithelial neoplasia grade 2 and 3.

Methods: 140 of 282 patients referred for colposcopy with two consecutive smears with atypical squamous cells of undetermined significance were only treated when abnormalities suggestive of high-grade cervical intraepithelial neoplasia were present at colposcopy. The other 142 patients underwent excision of all detected colposcopic abnormalities. Both groups were compared regarding the final cytological follow-up, the number of diathermy loop excisions, and the detection of cervical intraepithelial neoplasia. Retrospectively, the outcome of triage with high-risk human papillomavirus in the first group was investigated.

Results: There was no significant difference in final cytological follow-up between patients managed by expectative or by aggressive colposcopic management. Significantly less diathermy loop excisions (p < 0.001) are performed in case of expectative management. The sensitivity, specificity, negative- and positive predictive values of triage with high-risk human papillomavirus detection were comparable with those of colposcopy alone.

Conclusions: Patients referred with two consecutive ASC-US smears may be followed with an expectative colposcopic management and cytological follow-up. Triage with high-risk human papillomavirus will reduce the number of referrals and colposcopies, but (cytological) follow-up remains necessary in all high-risk human papillomavirus negative patients as well.

ASC-US; Management; Colposcopy; hr-HPV; Cytology

[1] W right T.C., Cox J.T., Massad LS., Twiggs L.B., Wilkinson E.J.: "2001 consensus guidelines for the management of women with cervical cytological abnormalities". JAMA, 2002, 287, 2120.

[2] Howell LP., Davis R.L.: "Follow-up Papanicolaou smears diagnosed as atypical squamous cells of undetermined significance". Dwgn Cytopathol., 1996, 14, 20.

[3] Baldauf J.J., Ritter J.: "Comparson of the risks of cytologic surveillance of women with atypical cells or low-grade abnormalities on cervical smear: review of the literature". Eur. J. Obstet. Gynecol. Reprod. Biol., 1998, 76, 193.

[4] Alanen K.W., Elit L.M., Molinaro P.A., McLachlin C.M.: "Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions". Cancer, 1998, 84, 5.

[5] Melnikow J., Nuovo J., Willan A.R., Chan B.K.S., Howell L.: "Natural history of cervical squamous intraepithelial neoplasia: A meta-analysis" Obstet. Gynecol., 1998, 92, 727.

[6] Kobelin M.H., Kobelin C.G., Burke L., Lavin P., Niloff J.M., Kim Y.B.: "Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears". Obstet. Gvnecol., 1998, 92, 356.

[7] Morin C., Bairati I.. Bouchard C., Fortier M., Roy M.. Moore L. et al.: "Cytologic predictors of cervical intraepithelial neoplasia m women with an ASC-US Pap smear". Acta Cyt., 2000, 44, 576.

[8] Malik S.N., Wilkinson E.J., Drew P.A., Bennett B.B., Hardt N.S.: "Do qualifiers of ASCUS distinguish between low- and high-risk patients" Acta Cytol., 1999, 43, 376.

[9] Solomon S., Schiffman M., Tarone R.: "Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. Baseline results from a randomized trial". J. Natl. Cancer Instil., 2001, 93, 293.

[10] Kinney W.K., Manos M.M., Hurley L.B., Ransley J.E.: "Where's the high-grade cervical neoplasia？The importance of minimally abnormal Papanicolaou diagnoses". Obstet. Gynecol., 1998, 91, 973.

[11] Giard R.W., Hermans J., Doornewaard H.: "National results of cervix cytology diagnosis in 1992; efficacy of screening could be improved" Ned Tijdsch1: Geneeskd., 1994, 138, 1325.

[12] Hanselaar A.G.: "Test for human papillomavirus: no added value by inclusion in improved population screening for cervical cancer at this point". Ned Tijdschr. Geneeskd., 2000, 144, 1668.

[13] Ferris D.G., Wright T.C., Litaker M.S., Richart R.M., Lorincz A.T., Sun X.W. et al.: "Triage of women with ASCUS and LSIL on Pap smear reports: Management by repeat Pap smear. HPV DNA testing, or colposcopy?". J Fam. Pract., 1998, 46, 125.

[14] Hopman E.H.. Kenemans P., Helmerhorst Th.J.M.: "The positive predictive rate of colposcopic examination of the cervix uteri: An overview of literature". Obstet. Gynecol. survey, 1998, 53, 97.

[15] Keijser K.G.G., Kenemans P., van der Zanden P.H., Schijf C.P., Yooys G.P.. Rolland R.: "Diathermy loop excision in the management of cervical intraepithelial neoplasia: diagnosis and treatment in one procedure". Am. J. Obstet. Gynecol., 1992, 166, 1281.

[16] Kerstens H.M., Robben J.C., Poddighe P.J., Melchers W.J., Boonstra H., de Wilde P.C. et al.: "Agarcyto: a novel cell-processing method for multiple molecular diagnostic analysis of the uterine cervix". J. Histochem. Cytochem., 2000, 48, 709.

[17] Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpten K.. Burger M. et al.: "Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses". Am. J. Pathol., 1998, 153, 1731.

[18] Quiny W.G.V., Scholte G., van Doorn L.J., Kleter B., Smits P.H.M., Lindeman J.: "Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping". J. Pathol., 2001, 194, 51.

[19] Melchers W.J., Bakkers J.M., Wang J., de Wilde P.C.M., Boonstra H., Quint W.G.V. et al.: "Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up" Am. J. Pathol., 1999, 155, 1473.

[20] Riethmuller D., Gay C., Bertrand X., Bettinger D., Schaal J.P., Carbillet J.P. et al.: "Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction". Diagn. Mol. Pathol., 1999, 8, 157.

[21] Perrons C., Kleter B., Jelley R., Jalal H., Quint W., Tedder R.: "Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/l l primers in cervical cells taken from women attending a colposcopy clinic". J. Med. Viral., 2002, 67, 246.

[22] Peyton C.L., Schiffman M., Lorincz A.T., Hunt W.C., Mielzynska I.. Bratti C. et al.: "Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies". J. Clin. Microbial., 1998, 36, 3248.

[23] Schneider A., Hoyer H., Lotz B., Leisritz S., Ki.ihne-Heid R., Nindl I. et al.: "Screening for high-grade cervical intraepithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy". Int. J. Cancer, 2000, 89, 529.

[24] Raab S.S.. Bishop N.S., Zaleski M.S.: "Long-term outcome and relative risk in women with atypical squamous cells of undetermined significance". Am. J. Clin. Pathol., 1999,112, 57.

[25] Sherman M.E., Schiffman M., Cox J.T.: "Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS)". J. Natl. Cancer Inst., 2002, 94, 102.

[26] Woodman C.B., Collins S., Winter H.. Bailey A., Ellis J., Prior P. et al.: "Natural history of cervical human papillomavirus infection m young women: a longitudinal cohort study". Lancet, 2001, 357, 1831.

[27] Giard R.W.M., Coebergh J.W.W.: "Population screening for cervical cancer; eventual gain not expected to increase by testing for papillomavirus". Ned. Tijdschr. Geneeskd., 2000, 144, 1664.

[28] Herbst A.L., Pickett K.E., Follen M., Noller K.L.: "The management of ASCUS cervical cytologic abnormalities and HPV testing: a cautionary note". Obstet. Gynecol., 2001, 98, 849.

[29] Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K. et al.: "Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study". Lancet, 1999, 354, 20.

[30] Lytwyn A., Sellors J.W.. Mahony J.B., Daya D., Chapman W., Ellis N. et al.: "Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPY effectiveness in low-grade Paps (HELP) study no. 1 group". CMAJ, 2000, 163, 701.

[31] Kim J.J.,W right T.C.,G oldie S.J.: "Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance" JAMA, 2002, 287, 2382.